Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

By Nikita Chaurasia  Date: 2021-01-04

Cadila Healthcare receives DCGI grant for phase 3 trials of ZyCoV-D

Indian pharmaceutical company Cadila Healthcare Limited, commonly known as Zydus Cadila, has made it to the headlines after receiving the approval of the DCGI (Drugs Controller General of India) for the Phase 3 clinical trials of its Coronavirus vaccine ZyCoV-D.

For the uninitiated, ZyCoV-D is a plasmid DNA, which translates into viral proteins when introduced into the host cells in order to trigger a robust immune response, facilitated by the humoral and cellular arms of the human immune system.

The Phase 3 trial round will include around 30000 volunteers. Sources confirmed that the company plans on initiating the launch as well as administration of the vaccine in the first quarter of the next financial year if the trial results are in its favor.

Reportedly, ZyCoV-D was proven to be well-tolerated, safe and immunogenic in its phase-1 and phase-2 clinical trials. It is also worth mentioning that the phase-2 trial round was conducted on around 1000 volunteers and included a randomized, multi-centric, dose-escalation double-blind placebo-controlled study.

The phase-2 trials were reviewed by an independent DSMB (Data Safety Monitoring Board) and the reports of the safety outcomes were submitted to the CDSCO (Central Drugs Standard Control Organization). Zydus Cadila then called for the DCGI approval after the phase-2 trials concluded positive outcomes.

Chairman of Zydus Group, Pankaj Patel was reported saying that the DCGI approval marks a significant milestone for the company’s vaccine development program. The phase-3 trials will ascertain the efficacy of ZyCoV-D in the treatment of Covid-19, he added.

The introduction of ZyCoV-D, developed in the company's Ahmedabad-based Vaccine Technology Centre, has paved the way for the establishment of a DNA vaccine platform in India, sources claimed. This platform has proven to improve vaccine stability and hence requires lower cold chain storage.

Moreover, Zydus Cadila has reportedly employed around 300 scientists to conduct comprehensive research on the vaccine, with around 1,400 researchers working on pharmaceutical technologies, biologicals and chemical entities (NCEs).

Source credits –

https://www.business-standard.com/article/current-affairs/zydus-gets-dcgi-nod-for-conducting-phase-3-clinical-trials-of-zycov-d-121010300466_1.html

About Author

Nikita Chaurasia     aeresearch.net

Nikita Chaurasia

An accomplished professional in the field of content development, playing with words comes naturally to Nikita Chaurasia. After completing her post-graduate MBA degree in Advertising and PR, Nikita worked across numerous content-driven verticals, undertaking diverse r...

Read More

More News By Nikita Chaurasia

CI NMF, Amp Energy India to jointly invest USD 200 Mn in renewables

CI NMF, Amp Energy India to jointly invest USD 200 Mn in renewables

By Nikita Chaurasia

Copenhagen Infrastructure Partners, one of the biggest renewable energy-centered fund managers worldwide, has signed an agreement with Amp Energy India Pvt Ltd. for joint equity investments of USD 200 million in renewables, using its Copenhagen Infra...

CDC updates guidelines, calls for vaccinated people to mask up

CDC updates guidelines, calls for vaccinated people to mask up

By Nikita Chaurasia

The Centers for Disease Control and Prevention issued new guidelines suggesting that people who are vaccinated against Covid-19 wear masks in public as well as indoor areas where the rate of the disease is high. The CDC also stated that teachers, sta...

iPhone’s hot streak could be hampered by global chip shortage crisis

iPhone’s hot streak could be hampered by global chip shortage crisis

By Nikita Chaurasia

Apple Inc. recently stated that the global chip shortage that has affected the sales of Macs and iPads, will now hit iPhone production and the expected revenue growth is likely to decelerate. This has resulted in lowering Apple’s shares. The c...

EV maker Rivian bags USD 2.5 Bn in a funding round led by Amazon, Ford

EV maker Rivian bags USD 2.5 Bn in a funding round led by Amazon, Ford

By Nikita Chaurasia

American electric vehicle maker Rivian Automotive LLC reportedly secured USD 2.5 billion in a funding round led by Amazon.com Inc, T. Rowe Price, D1 Capital Partners, and Ford Motor Co. In addition, the event also saw participation from Fidelity Man...

ICEA forms committee chaired by HP India MD to boost IT hardware sector

ICEA forms committee chaired by HP India MD to boost IT hardware sector

By Nikita Chaurasia

The India Cellular & Electronics Association (ICEA) recently announced the formation of a committee to promote manufacturing and exports of the IT hardware sector. The panel headed by Ketan Patel, HP India’s Managing Director, will set up a...